Boehringer, Envisagenics to develop precision cancer therapies

Boehringer Ingelheim and Envisagenics have entered into a research collaboration and option agreement aimed at validating tumour-specific targets for the development of precision therapies in solid tumours. The partnership will focus on targets identified through Envisagenics’ SpliceCore AI platform. The partnership intends to validate selected tumour-specific targets for therapies that selectively attack cancer cells while reducing impact. Credit: luchschenF / Shutterstock.com. Boehringer Ingelheim and Envisagenics have entered a research collaboration and option agreement that aims to validate tumour-specific targets for the development of precision therapies in solid tumours. Under the agreement, Envisagenics is set to receive more than $1bn through…

Source: Pharmaceutical Technology